by The global intravenous immunoglobulin market size accounted for US$ 13.69 Bn in 2022 and is projected to reach around USD 29.53 Bn by 2032, growing at a CAGR of 7.99% from 2023 to 2032.
Report Summary
The global intravenous immunoglobulin market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the intravenous immunoglobulin market across the globe.
A comprehensive estimate on the intravenous immunoglobulin market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of intravenous immunoglobulin during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2996
Intravenous Immunoglobulin Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 14.78 Billion |
| Market Size by 2032 | USD 29.53 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 7.99% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Product, By Route of Administration, By Application, By End-Users, and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized intravenous immunoglobulin market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: High Barrier Packaging Films Market Size Analysis 2023 To 2032
Intravenous Immunoglobulin Market Players
The report includes the profiles of key intravenous immunoglobulin market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Major companies operating in this area
- Biotest AG
- Octapharma AG
- LFB Biotechnologies
- Grifols SA
- CSL Behring
- China Biologics Products Inc.
- Kedrion Biopharma
- BDI Pharma Inc.
Market Segmentation
By Product
- IGG
- IGA
- IGM
- IGE
- IGD
By Route of Administration
- Intravenous
- Subcutaneous
By Application
- Hypogammaglobulinemia
- Chronic Inflammatory demyelinating polyneuropathy (CIDP)
- Immunodeficiency diseases
- Myasthenia Gravis
- Multifocal motor neuropathy
- Idiopathic thrombocytopenic purpura (ITP)
- Inflammatory myopathies
- Specific antibody deficiency
- Guillain-Barre syndrome
By End-Users
- Hospitals
- Homecare
- Specialty Clinics
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Intravenous Immunoglobulin Market
5.1. COVID-19 Landscape: Intravenous Immunoglobulin Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Intravenous Immunoglobulin Market, By Product
8.1. Intravenous Immunoglobulin Market Revenue and Volume, by Product, 2023-2032
8.1.1. IGG
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. IGA
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. IGM
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
8.1.4. IGE
8.1.4.1. Market Revenue and Volume Forecast (2020-2032)
8.1.5. IGD
8.1.5.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Intravenous Immunoglobulin Market, By Route of Administration
9.1. Intravenous Immunoglobulin Market Revenue and Volume, by Route of Administration, 2023-2032
9.1.1. Intravenous
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Subcutaneous
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Intravenous Immunoglobulin Market, By Application
10.1. Intravenous Immunoglobulin Market Revenue and Volume, by Application, 2023-2032
10.1.1. Hypogammaglobulinemia
10.1.1.1. Market Revenue and Volume Forecast (2020-2032)
10.1.2. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
10.1.2.1. Market Revenue and Volume Forecast (2020-2032)
10.1.3. Immunodeficiency diseases
10.1.3.1. Market Revenue and Volume Forecast (2020-2032)
10.1.4. Myasthenia Gravis
10.1.4.1. Market Revenue and Volume Forecast (2020-2032)
10.1.5. Multifocal motor neuropathy
10.1.5.1. Market Revenue and Volume Forecast (2020-2032)
10.1.6. Idiopathic thrombocytopenic purpura (ITP)
10.1.6.1. Market Revenue and Volume Forecast (2020-2032)
10.1.7. Inflammatory myopathies
10.1.7.1. Market Revenue and Volume Forecast (2020-2032)
10.1.8. Specific antibody deficiency
10.1.8.1. Market Revenue and Volume Forecast (2020-2032)
10.1.9. Guillain-Barre syndrome
10.1.9.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 11. Global Intravenous Immunoglobulin Market, By End-Users
11.1. Intravenous Immunoglobulin Market Revenue and Volume, by End-Users, 2023-2032
11.1.1. Hospitals
11.1.1.1. Market Revenue and Volume Forecast (2020-2032)
11.1.2. Homecare
11.1.2.1. Market Revenue and Volume Forecast (2020-2032)
11.1.3. Specialty Clinics
11.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 12. Global Intravenous Immunoglobulin Market, By Distribution Channel
12.1. Intravenous Immunoglobulin Market Revenue and Volume, by Distribution Channel, 2023-2032
12.1.1. Hospital Pharmacy
12.1.1.1. Market Revenue and Volume Forecast (2020-2032)
12.1.2. Retail Pharmacy
12.1.2.1. Market Revenue and Volume Forecast (2020-2032)
12.1.3. Online Pharmacies
12.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 13. Global Intravenous Immunoglobulin Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.1.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.1.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.1.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.1.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.1.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.1.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.1.6.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.1.7.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.1.7.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.1.7.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.2.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.2.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.2.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.2.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.2.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.2.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.2.7. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.2.8. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.2.9.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.2.9.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.2.10. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.2.11. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.2.12.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.2.12.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.2.12.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.2.13. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.2.14.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.2.14.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.2.14.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.2.15. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.3.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.3.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.3.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.3.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.3.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.3.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.3.6.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.3.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.3.8.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.3.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.3.8.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.3.9. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.3.10.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.3.10.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.3.10.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.3.11.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.3.11.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.3.11.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.4.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.4.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.4.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.4.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.4.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.4.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.4.6.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.4.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.4.8.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.4.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.4.8.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.4.9. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.4.10.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.4.10.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.4.10.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.4.11.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.4.11.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.4.11.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.5.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.5.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.5.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.5.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.5.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.5.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.5.6.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.5.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.5.8.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.5.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.5.8.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
Chapter 14. Company Profiles
14.1. Biotest AG
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Octapharma AG
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. LFB Biotechnologies
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Grifols SA
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. CSL Behring
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. China Biologics Products Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Kedrion Biopharma
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. BDI Pharma Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
